¡Pará un Cacho!: letras misóginas de un cantante popular

Traemos para compartir un trabajo realizado en la Cátedra de Estética / Fundamentos Estéticos, comisión siete. Este trabajo es de participación grupal, realizado bajo una consigna común a todas las comisiones de la cátedra, siendo su aceptación requisito para la aprobación de la asignatura. La modalidad de trabajo consistió en elaborar, desde el marco teórico (bibliografía de las unidades del programa), un escrito abordando producciones artísticas de alguno/os integrantes del grupo, produciendo un artículo de arte en formato de publicación para revista cultural. De este modo la producción “Los machos dicen. No al discurso machista”, obra de arte de acción participativa que fuera realizada en el patio de la sede Fonseca de nuestra Facultad, es abordada por los integrantes del grupo, con una otra mirada, problematizadora y enriquecida desde lo conceptual. La obra seleccionada para su análisis plantea desde el arte una reflexión acerca de la violencia implícita y explícita contra la mujer en canciones populares, en este caso aquella de Cacho Castaña: “Si te agarro con otro te mato”; en relación que estas producciones reproducen, naturalizan y fomentan las prácticas violentas hacia la mujer.Facultad de Bellas Arte

¡Pará un Cacho!: letras misóginas de un cantante popular

Traemos para compartir un trabajo realizado en la Cátedra de Estética / Fundamentos Estéticos, comisión siete. Este trabajo es de participación grupal, realizado bajo una consigna común a todas las comisiones de la cátedra, siendo su aceptación requisito para la aprobación de la asignatura. La modalidad de trabajo consistió en elaborar, desde el marco teórico (bibliografía de las unidades del programa), un escrito abordando producciones artísticas de alguno/os integrantes del grupo, produciendo un artículo de arte en formato de publicación para revista cultural. De este modo la producción “Los machos dicen. No al discurso machista”, obra de arte de acción participativa que fuera realizada en el patio de la sede Fonseca de nuestra Facultad, es abordada por los integrantes del grupo, con una otra mirada, problematizadora y enriquecida desde lo conceptual. La obra seleccionada para su análisis plantea desde el arte una reflexión acerca de la violencia implícita y explícita contra la mujer en canciones populares, en este caso aquella de Cacho Castaña: “Si te agarro con otro te mato”; en relación que estas producciones reproducen, naturalizan y fomentan las prácticas violentas hacia la mujer.Facultad de Bellas Arte

¡Pará un Cacho!: letras misóginas de un cantante popular

Traemos para compartir un trabajo realizado en la Cátedra de Estética / Fundamentos Estéticos, comisión siete. Este trabajo es de participación grupal, realizado bajo una consigna común a todas las comisiones de la cátedra, siendo su aceptación requisito para la aprobación de la asignatura. La modalidad de trabajo consistió en elaborar, desde el marco teórico (bibliografía de las unidades del programa), un escrito abordando producciones artísticas de alguno/os integrantes del grupo, produciendo un artículo de arte en formato de publicación para revista cultural. De este modo la producción “Los machos dicen. No al discurso machista”, obra de arte de acción participativa que fuera realizada en el patio de la sede Fonseca de nuestra Facultad, es abordada por los integrantes del grupo, con una otra mirada, problematizadora y enriquecida desde lo conceptual. La obra seleccionada para su análisis plantea desde el arte una reflexión acerca de la violencia implícita y explícita contra la mujer en canciones populares, en este caso aquella de Cacho Castaña: “Si te agarro con otro te mato”; en relación que estas producciones reproducen, naturalizan y fomentan las prácticas violentas hacia la mujer.Facultad de Bellas Arte

Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment : results of the MOPEAD Study in Spain

Altres ajuts: This research was funded by the European Innovative Medicines Initiative (IMI2) Project-grant number 115985.Introduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitive impairment in type 2 diabetes (T2D) patients attended in a third-level hospital. Material and Methods: T2D patients > 65 years, without known cognitive impairment, attended in a third-level hospital, were evaluated. As per MOPEAD protocol, patients with MMSE ≤ 27 or DSDRS ≥ 7 were referred to the memory clinic for complete neuropsychological assessment. Results: 112 T2D patients were recruited. A total of 82 fulfilled the criteria for referral to the memory unit (43 of them declined referral: 48.8% for associated comorbidities, 37.2% lack of interest, 13.95% lack of social support). At the Fundació ACE's Memory Clinic, 34 cases (87.2%) of mild cognitive impairment (MCI) and 3 cases (7.7%) of dementia were diagnosed. The predictive value of DSDRS ≥ 7 as a screening tool of cognitive impairment was AUROC = 0.739, p 0.024, CI 95% (0.609-0.825). Conclusions: We found a high prevalence of unknown cognitive impairment in TD2 patients who attended a third-level hospital. The DSDRS was found to be a useful screening tool. The presence of associated comorbidities was the main factor of declining referral

Pre‐screening models for patient engagement: The MOPEAD project

AbstractBackgroundAlzheimer's disease (AD) is a devastating condition that not only impacts greatly on the patient's health but also poses an important burden on the patient's immediate family circle. Early detection of AD allows patients to have an active role in managing their condition, and to plan how to minimize the strain on their dear ones. Despite known benefits, a large proportion of dementia cases remains undiagnosed or receives a late stage diagnosis. The MOPEAD project aims to address this issue by exploring innovative strategies to emerge "hidden" cases of cognitive impairment.MethodMemory clinics located in five different European countries participated in the project. Four innovative pre‐screening strategies were implemented to detect cognitive decline among individuals aged 65‐85 years who had never received a dementia related diagnosis: a) a web‐based pre‐screening tool along with an online marketing campaign, b) open house initiatives where people with memory complaints were invited to receive a quick evaluation at participating memory clinics, c) a primary care‐based protocol for early detection of cognitive decline using easily administered tools, and d) a tertiary care‐based pre‐screening at diabetologist clinics specifically designed to assess risk of dementia among patients with diabetes. A positive pre‐screening result implied that individuals were at high risk of having mild cognitive impairment or AD.ResultThe number of individuals enrolled, and the proportion of those with positive pre‐screening results varied across strategies. The web‐based tool evaluated the largest number of individuals (n=1487) and yielded 547 positive results (36.8%). The Open house initiative pre‐screened 661 subjects of whom 235 (35.6%) obtained a positive result. A total of 435 patients were pre‐screened in the primary care‐based strategy and 193 of them (44.4%) were found to have a positive result. Finally, 264 patients from diabetes clinics underwent pre‐screening and 154 (58.3%) showed a positive result.ConclusionUsing innovative pre‐screening strategies, we were able to identify 1129 individuals at high risk of having dementia who had otherwise remained unnoticed. Initiatives like this, show us the way to go in order to shift the paradigm of AD towards an earlier diagnosis

Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease : Results from the MOPEAD project

The Models of Patient Engagement for Alzheimer's Disease (MOPEAD) project was conceived to explore innovative complementary strategies to uncover hidden prodromal and mild Alzheimer's disease (AD) dementia cases and to raise awareness both in the general public and among health professionals about the importance of early diagnosis. Four different strategies or RUNs were used: (a) a web-based (WB) prescreening tool, (2) an open house initiative (OHI), (3) a primary care-based protocol for early detection of cognitive decline (PC), and (4) a tertiary care-based pre-screening at diabetologist clinics (DC). A total of 1129 patients at high risk of having prodromal AD or dementia were identified of 2847 pre-screened individuals (39.7%). The corresponding proportion for the different initiatives were 36.8% (WB), 35.6% (OHI), 44.4% (PC), and 58.3% (DC). These four complementary pre-screening strategies were useful for identifying individuals at high risk of having prodromal or mild AD

Identification of undiagnosed dementia cases using a web-based pre-screening tool: The MOPEAD project

Introduction Innovative patient engagement models are required to identify people with prodromal and mild Alzheimer's disease who are hidden in their communities and not normally found in a memory clinic setting. Methods A marketing campaign and a web-based pre-screening tool were used to identify individuals at risk of dementia in five European countries. Harmonized clinical evaluation of these patients was performed in participating memory clinics within the MOPEAD project. Results A total of 1487 individuals completed the pre-screening, with 547 of them found to be at risk of dementia (36.8%). Among the subset of 91 patients with a positive pre-screening result that underwent full clinical evaluation, 49 (53.8%) were diagnosed with either mild cognitive impairment or Alzheimer's disease. Conclusion This novel web-based pre-screening tool showed to be a valid strategy to identify undiagnosed people with cognitive impairment

Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment : results of the MOPEAD Study in Spain

Altres ajuts: This research was funded by the European Innovative Medicines Initiative (IMI2) Project-grant number 115985.Introduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitive impairment in type 2 diabetes (T2D) patients attended in a third-level hospital. Material and Methods: T2D patients > 65 years, without known cognitive impairment, attended in a third-level hospital, were evaluated. As per MOPEAD protocol, patients with MMSE ≤ 27 or DSDRS ≥ 7 were referred to the memory clinic for complete neuropsychological assessment. Results: 112 T2D patients were recruited. A total of 82 fulfilled the criteria for referral to the memory unit (43 of them declined referral: 48.8% for associated comorbidities, 37.2% lack of interest, 13.95% lack of social support). At the Fundació ACE's Memory Clinic, 34 cases (87.2%) of mild cognitive impairment (MCI) and 3 cases (7.7%) of dementia were diagnosed. The predictive value of DSDRS ≥ 7 as a screening tool of cognitive impairment was AUROC = 0.739, p 0.024, CI 95% (0.609-0.825). Conclusions: We found a high prevalence of unknown cognitive impairment in TD2 patients who attended a third-level hospital. The DSDRS was found to be a useful screening tool. The presence of associated comorbidities was the main factor of declining referral

A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project

Background: For care planning and support, under-detection and late diagnosis of Alzheimer's disease (AD) is a great challenge. Models of Patient-Engagement for Alzheimer's Disease (MOPEAD) is an EU-funded project aiming at testing different strategies to improve this situation. Objective: To make a cost-consequence analysis of MOPEAD. Methods: Four screening strategies were tested in five countries (Germany, the Netherlands, Slovenia, Spain, and Sweden): 1) a web-approach; 2) Open-House initiative; 3) in primary care; and 4) by diabetes specialists. Persons-at-risk of AD in all strategies were offered referral to a hospital-based specialist. The primary health-economic outcome was the cost per true-positive case (TP) of AD from the screened population. Results: Of 2,847 screened persons, 1,121 screened positive (39%), 402 were evaluated at memory clinics (14%), and 236 got an AD diagnosis (8%). The cost per TP of those screened was (sic)3,115 with the web-approach, (sic)2,722 with the Open-House, (sic)1,530 in primary care, and (sic)1,190 by diabetes specialists. Sensitivity analyses that more likely reflect the real-world situation confirmed the results. The number-needed-to-screen was 30 with the web-approach, 8 with the Open-House and primary care, and 6 with the diabetes specialists. There were country differences in terms of screening rates, referrals to memory clinics, staff-types involved, and costs per TP. Conclusion: In primary care and by the diabetes specialist, the costs per TP/screened population were lowest, but the capacity of such settings to identify cases with AD-risk must be discussed. Hence new diagnostic strategies such as web-solutions and Open-House initiatives may be valuable after modifications

Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease : Results from the MOPEAD project

Introduction: The Models of Patient Engagement for Alzheimer's Disease (MOPEAD) project was conceived to explore innovative complementary strategies to uncover hidden prodromal and mild Alzheimer's disease (AD) dementia cases and to raise awareness both in the general public and among health professionals about the importance of early diagnosis. Methods: Four different strategies or RUNs were used: (a) a web-based (WB) prescreening tool, (2) an open house initiative (OHI), (3) a primary care–based protocol for early detection of cognitive decline (PC), and (4) a tertiary care–based pre-screening at diabetologist clinics (DC). Results: A total of 1129 patients at high risk of having prodromal AD or dementia were identified of 2847 pre-screened individuals (39.7%). The corresponding proportion for the different initiatives were 36.8% (WB), 35.6% (OHI), 44.4% (PC), and 58.3% (DC). Conclusion: These four complementary pre-screening strategies were useful for identifying individuals at high risk of having prodromal or mild AD